Etidronate for treatment of osteoporosis

Shogo Asano, Atsushi Suzuki, Mitsuyasu Itoh

研究成果: Review article査読

抄録

The treatment with anti-resorptive agents including bisphosphonates and selective estrogen receptor modulators (SERM) has clinical relevance to reduce osteoporotic fractures in postmenopausal women. Among them, etidronate has a unique mechanism to suppress osteoclastic activity, and could be used to treat long-term immobilized patients, to whom other bisphosphonates or SERM are not available because of their adverse effects. In addition, intermittent therapy regimen (two weeks every three months) and less gastroesophageal reflux disorder may be suitable for some patients. Etidronate has less and lower clinical evidences than other bisphosphonates and SERM, but still has clinical efficacy and advantage to treat osteoporotic patients.

本文言語English
ページ(範囲)938-942
ページ数5
ジャーナルNippon rinsho. Japanese journal of clinical medicine
67
5
出版ステータスPublished - 05-2009

All Science Journal Classification (ASJC) codes

  • 医学(全般)

フィンガープリント

「Etidronate for treatment of osteoporosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル